Mauna Kea was the second biggest riser on the CAC Mid & Small index on Friday morning on the Paris Bourse after the medical technology company announced positive results from a clinical study in lung cancer.

The study, involving 20 patients, supported the potential of its needle-based laser endomicroscopy to reduce the current rate of missed targets, improve diagnostic yield and thus avoid false negatives during bronchoscopic assessments of lung nodules.

Mauna Kea reports that its bronchoscopic imaging confirmed correct targeting of the needle into the nodule in 19 of 20 patients (95%), while the corresponding rapid on-site cytological evaluation confirmed the presence of representative material in only nine of 20 patients (45%).

No complications were reported during the study.

Of the 17 patients presenting with malignancy, 16 (94%) had their final diagnosis of lung cancer confirmed by nCLE imaging.

At 10.50 a.m., Mauna Kea was up 9.5% in volumes already four times higher than the previous day, while the CAC Mid & Small index was up 0.9%. The share price has risen by 17.7% since January 1.

Copyright (c) 2023 CercleFinance.com. All rights reserved.